[go: up one dir, main page]

MX2008010921A - Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados. - Google Patents

Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados.

Info

Publication number
MX2008010921A
MX2008010921A MX2008010921A MX2008010921A MX2008010921A MX 2008010921 A MX2008010921 A MX 2008010921A MX 2008010921 A MX2008010921 A MX 2008010921A MX 2008010921 A MX2008010921 A MX 2008010921A MX 2008010921 A MX2008010921 A MX 2008010921A
Authority
MX
Mexico
Prior art keywords
products
processes
morphinan
unsaturated ketone
beta
Prior art date
Application number
MX2008010921A
Other languages
English (en)
Inventor
Anthony Mannino
Hong Gu
Henry J Buehler
William E Dummitt
Dennis C Aubuchon
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38326629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008010921(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of MX2008010921A publication Critical patent/MX2008010921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere en general a procesos para preparar productos de morfinan-6-ona altamente puros. Los procesos involucran reducir la concentración de los compuestos de cetonas alfa, beta insaturadas presentes como impurezas en los productos de morfinan-6-ona o mezclas de reacción que incluyen compuestos de morfinan-6-ona mediante tratamiento con un compuesto que contiene azufre.
MX2008010921A 2006-03-02 2007-03-02 Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados. MX2008010921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77825806P 2006-03-02 2006-03-02
PCT/US2007/005256 WO2007103105A2 (en) 2006-03-02 2007-03-02 Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds

Publications (1)

Publication Number Publication Date
MX2008010921A true MX2008010921A (es) 2008-09-03

Family

ID=38326629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010921A MX2008010921A (es) 2006-03-02 2007-03-02 Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados.

Country Status (10)

Country Link
US (8) US8871779B2 (es)
EP (1) EP1994034B1 (es)
JP (2) JP5695296B2 (es)
CN (1) CN101395159A (es)
AT (1) ATE448231T1 (es)
AU (1) AU2007224221B2 (es)
CA (1) CA2644095A1 (es)
DE (1) DE602007003197D1 (es)
MX (1) MX2008010921A (es)
WO (1) WO2007103105A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
MX2008006710A (es) 2005-11-22 2008-12-16 Controlled Chemicals Inc Procedimientos para reducir niveles de aceptor de michael contaminantes en oxicodona y otras composiciones.
AU2007224221B2 (en) 2006-03-02 2013-02-14 SpecGx LLC Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
US20080125592A1 (en) 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
EP2073636B1 (en) * 2006-10-17 2012-09-05 Penick Corporation Process for preparing oxymorphone
JP2010511726A (ja) 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
AU2007329451B2 (en) 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
FR2923484B1 (fr) 2007-11-09 2012-11-09 Sanofi Aventis Procede de preparation de composes morphiniques
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
MX2012000317A (es) 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
AU2011274361B2 (en) * 2010-07-02 2014-09-18 Macfarlan Smith Limited Process for the synthesis and purification of oxycodone
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
TWI560170B (en) 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
TR201815502T4 (tr) 2012-04-18 2018-11-21 Gruenenthal Gmbh Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US20150259355A1 (en) 2012-07-16 2015-09-17 Rhodes Technologies Process for improved opioid synthesis
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
GB201313211D0 (en) * 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
US9120800B2 (en) 2013-08-02 2015-09-01 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone alkaloid and oxymorphone salts
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
MX374394B (es) 2014-01-15 2025-03-06 Rhodes Tech Proceso para la sintesis mejorada de oxicodona.
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
MA40332A (fr) * 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
WO2016187522A1 (en) * 2015-05-20 2016-11-24 Noramco, Inc. Process for the preparation of oxymorphone freebase
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US20230399334A1 (en) * 2020-11-02 2023-12-14 Rhodes Technologies Process for purifying noroxymorphone
CN114634514B (zh) * 2022-04-14 2024-04-09 甘肃农垦药物碱厂有限公司 一种去甲羟吗啡酮中杂质的去除方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009181A (en) * 1935-07-23 Process for obtaining opium alka
US1479293A (en) * 1924-01-01 Hiabtor fbettlid
FR1000543A (fr) 1946-02-26 1952-02-13 Roussel Uclaf Procédé d'extraction des alcaloïdes de l'opium
GB713689A (en) 1952-02-08 1954-08-18 T And H Smith Ltd A process for the extraction of alkaloids from poppy straw and/or capsules
US4435572A (en) * 1978-04-26 1984-03-06 The United States Of America As Represented By The Department Of Health And Human Services Synthesis of ethyl-4(3'-methoxyphenyl)-1-methyl piperidine-3-carboxylate
NO793297L (no) 1978-10-19 1980-04-22 Mallinckrodt Inc Fremgangsmaate til fremstilling av oksymorfon
JPS55102538A (en) * 1979-01-30 1980-08-05 Kawasaki Kasei Chem Ltd Preparation of p-n-alkyl benzoate
IT1129758B (it) * 1980-01-23 1986-06-11 Montedison Spa Processo per la riduzione catalitica di chetoni insaturi
US4410700A (en) * 1980-07-03 1983-10-18 The United States Of America As Represented By The Department Of Health And Human Services Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution
US4727146A (en) * 1980-07-03 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by asymmetric reduction
US4368326A (en) * 1980-07-03 1983-01-11 Rice Kenner C Short total synthesis of dihydrothebainone, dihydrocodeinone, and nordihydroccodeinone
US4556712A (en) * 1981-05-20 1985-12-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation and racemization of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines
US4521601A (en) * 1981-05-20 1985-06-04 The United States Of America As Represented By The Department Of Health & Human Services Practical total synthesis unnatural enantiomers of opium-derived morphinans
US4613668A (en) * 1983-12-22 1986-09-23 The United States Of America As Represented By The Department Of Health And Human Services Short total synthesis or morphinan compounds which uses cyclization of a cycloalkylcarbonyl compound selected from cyclopropylcarbonyl and cyclobutylcarbonyl
JPS60193902A (ja) 1984-03-16 1985-10-02 Mitsui Toatsu Chem Inc 害虫防除用組成物
US5459264A (en) 1992-12-21 1995-10-17 Shionogi Seiyaku Kabushiki Kaisha Method for reducing an α β-unsaturated ketone
HU223345B1 (hu) * 1995-12-20 2004-08-30 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Eljárás alfa, béta-telítetlen ketonok sztereoszelektív redukciójára
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
WO2006084389A1 (de) 2005-02-11 2006-08-17 Cilag Ltd. Verfahren zur reinigung von noroxymorphon-verbindungen
CA2598774C (en) * 2005-03-04 2010-12-21 Euro-Celtique S.A. Method of reducing alpha, beta unsaturated ketones in opioid compositions
MX2008006710A (es) * 2005-11-22 2008-12-16 Controlled Chemicals Inc Procedimientos para reducir niveles de aceptor de michael contaminantes en oxicodona y otras composiciones.
AU2007224221B2 (en) * 2006-03-02 2013-02-14 SpecGx LLC Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
EP2073636B1 (en) * 2006-10-17 2012-09-05 Penick Corporation Process for preparing oxymorphone
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
CA2681740A1 (en) * 2007-03-23 2008-10-02 Mallinckrodt Inc. Improved preparation of oxymorphone from oripavine

Also Published As

Publication number Publication date
US8871779B2 (en) 2014-10-28
US20080312442A1 (en) 2008-12-18
US20220079938A1 (en) 2022-03-17
CA2644095A1 (en) 2007-09-13
EP1994034A2 (en) 2008-11-26
JP5695296B2 (ja) 2015-04-01
US20150148365A1 (en) 2015-05-28
DE602007003197D1 (de) 2009-12-24
US20190381033A1 (en) 2019-12-19
US20200338068A1 (en) 2020-10-29
JP2013173765A (ja) 2013-09-05
ATE448231T1 (de) 2009-11-15
WO2007103105A2 (en) 2007-09-13
US20180008596A1 (en) 2018-01-11
US20120059167A1 (en) 2012-03-08
JP2009528366A (ja) 2009-08-06
US20160243113A1 (en) 2016-08-25
CN101395159A (zh) 2009-03-25
US8748611B2 (en) 2014-06-10
AU2007224221B2 (en) 2013-02-14
AU2007224221A1 (en) 2007-09-13
WO2007103105A3 (en) 2007-11-22
EP1994034B1 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
MX2008010921A (es) Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados.
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
MY157365A (en) Chemical compounds and uses
WO2008013840A3 (en) Erastin analogs and uses thereof
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
SI1881967T1 (sl) Substituirane benzo(d)izoksazol-3-il-aminske spojine kot analgetiki
TW200612892A (en) Novel compounds
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
IL187586A0 (en) Method for producing dihydroquinazolines
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
PL1861405T3 (pl) Sposób redukcji alfa, beta -nienasyconych ketonów w kompozycjach opioidowych
IL222787A0 (en) Process for preparing nebivolol
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
PH12012501052A1 (en) Novel spiropiperidine compounds
WO2008073332A3 (en) Creatine compositions for skin treatment
MX2009007695A (es) Compuestos complejos de carbohidrato de hierro.
MY151017A (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
TW200700071A (en) Novel use
IL183104A0 (en) Method for production of candesartan
SI1831239T1 (sl) Postopek za pripravo gamma laktona hidroksi beta beta beta beta bismetilen alfa pregn en on karboksilne kisline in ključniintermediati za ta postopek
TW200738650A (en) Process for synthesis of aryloxy diaminopyrimidines
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.
UA33424U (ru) Способ синтеза энантиомерно чистого и химически чистого 3,4-метанопролина

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status